Subscribe

FunPep Company Limited (4881.T)

JPY74.00 +0.00 (+0.00%)
JP JPX Healthcare Biotechnology
Address No.7 Mizuho Building 151-0051
Tokyo, JP
CEO Toshimi Miyoshi
Website funpep.co.jp
IPO 2020-12-25
ISIN JP3802640007

Explore sections of this company profile

Description

FunPep Company Limited specializes in the discovery and advancement of pharmaceutical drugs, functional cosmetics, and medical devices, leveraging its core technology in functional peptides. The company's development pipeline prominently features SR-0379, a functional peptide designed to address skin ulcers. FunPep is advancing FPP003, an antibody-inducing peptide, which is undergoing Phase II clinical trials for psoriasis in Australia and for ankylosing spondylitis in Japan. Another antibody-inducing peptide, FPP004X, is also in development, targeting pollinosis. Additionally, the company is working on FPP006, a corona peptide vaccine, and FPP005, an antibody-inducing peptide for psoriasis. Established in 2013, FunPep Company Limited operates from its headquarters in Tokyo, Japan.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
JPY74.00 +0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
809.9K
Beta
0.83
Float Shares
36.71M
Free Float %
89.7%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-1.47% -4.29% -14.10% -25.56% -26.37% -17.28% -34.95% -64.55% -83.82% -91.41% -91.41%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
74.00
DCF (Unlevered) 46.87 -36.7%
DCF (Levered) 46.41 -37.3%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM)
Rating 2024-11 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
-0.38
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Biotechnology: +1.6%
    -94.9% Q1'26: +0.0% (vs Q1'25)
  • ✗
    EPS growth Biotechnology: +29.7%
    -57.0% Q1'26: +61.5% (vs Q1'25)
  • ✗
    FCF margin FCF growth · Biotechnology: +16.2%
    -419,580.9% Q1'26: +0.0% (vs Q1'25)
  • ✗
    EBIT margin Biotechnology: +0.0%
    -525,053.5% Q1'26: -565,430.8% (vs Q1'25)
  • ✓
    ROIC Biotechnology: -16.1%
    — Q1'26: +426.9% (vs Q1'25)
  • ✗
    Share dilution Biotechnology: -3.4%
    +37.0% Q1'26: +26.2% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples From To
DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.86) × ERP
WACC = 100% × Ke + 0% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 46.87 Current price: 74.00
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana. 		Dec 2029
1 Rev. Ana. 		Dec 2030
1 Rev. Ana.
Revenue
6.13M
est: 100.00M (-93.9%)
314.0K
est: 400.00M (-99.9%)
300.00M
300.00M – 300.00M
-25.0% YoY
500.00M
500.00M – 500.00M
+66.7% YoY
727.00M
727.00M – 727.00M
+45.4% YoY
943.00M
943.00M – 943.00M
+29.7% YoY
581.00M
581.00M – 581.00M
-38.4% YoY
EBITDA
-859.23M
est: -100.00M (-759.2%)
-1.61B
est: -400.00M (-301.7%)
-300.00M
-300.00M – -300.00M
+25.0% YoY
-500.00M
-500.00M – -500.00M
-66.7% YoY
-727.00M
-727.00M – -727.00M
-45.4% YoY
-943.00M
-943.00M – -943.00M
-29.7% YoY
-581.00M
-581.00M – -581.00M
+38.4% YoY
EBIT
-901.76M
est: -100.00M (-801.8%)
-1.65B
est: -400.00M (-312.2%)
-300.00M
-300.00M – -300.00M
+25.0% YoY
-500.00M
-500.00M – -500.00M
-66.7% YoY
-727.00M
-727.00M – -727.00M
-45.4% YoY
-943.00M
-943.00M – -943.00M
-29.7% YoY
-581.00M
-581.00M – -581.00M
+38.4% YoY
Net Income
-889.09M
est: -1.50B (+40.7%)
-1.91B
est: -1.64B (-16.5%)
-757.75M
-757.75M – -757.75M
+53.8% YoY
-673.98M
-673.98M – -673.98M
+11.1% YoY
-605.44M
-605.44M – -605.44M
+10.2% YoY
—
— – —
+100.0% YoY
—
— – —
SGA
295.47M
est: 35.12B (-99.2%)
311.07M
est: 140.46B (-99.8%)
105.35B
105.35B – 105.35B
-25.0% YoY
175.58B
175.58B – 175.58B
+66.7% YoY
255.29B
255.29B – 255.29B
+45.4% YoY
331.14B
331.14B – 331.14B
+29.7% YoY
204.02B
204.02B – 204.02B
-38.4% YoY
EPS
-31.98
est: -39.40 (+18.8%)
-50.20
est: -43.10 (-16.5%)
-19.90
-19.90 – -19.90
+53.8% YoY
-17.70
-17.70 – -17.70
+11.1% YoY
-15.90
-15.90 – -15.90
+10.2% YoY
—
— – —
+100.0% YoY
—
— – —
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-11 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-05-08 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-05-07 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-05-01 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-30 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-28 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-27 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-24 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-23 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-22 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-21 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-20 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-17 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-16 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
278.9K
OE per share TTM
0.01
Owner's Yield
0.01%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
5.8%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
-1.10M
Shares Outstanding
40.92M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Hideki Tomioka CSO, Director of R&D and Director — male
Koshi Koseki Executive Manager of Legal & Intellectual Property — —
Susumu Tsuchiya Executive Manager of General Affairs & HR — —
Taketoshi Hayashi Chief Financial Officer, GM of Administration & Director — male
Toshimi Miyoshi Chairman, President & Chief Executive Officer — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Biotechnology